• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

    9/20/24 9:15:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    • Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers 
    • Accelerates the development of Navista oncology practice alliance, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states

    DUBLIN, Ohio, Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that it has entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.115B in cash. ION includes more than 50 practice sites in 10 states representing more than 100 providers with extensive reach into the local communities they serve. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology, diagnostic testing and other ancillary services.

    Cardinal Health Logo (PRNewsfoto/Cardinal Health)

    The transaction builds on Cardinal Health's commitment to helping community healthcare providers maintain their independence. As part of the transaction ION practices will become members of Navista, Cardinal Health's oncology practice alliance, and ION practice management and practice growth services will become part of Navista's advanced services and technology offering. ION practices will also have access to Navista's advanced analytics capabilities that leverage artificial intelligence as well as deep expertise from Specialty Networks' PPS Analytics and SoNaR technology solutions to generate actionable clinical and business insights.

    "Driving growth in specialty continues to be a top priority, and we've made investments to expand our offerings through both Navista and our acquisition of Specialty Networks," said Jason Hollar, CEO, Cardinal Health. "With their proven model providing extensive support of community oncology across the cancer care continuum and healthcare ecosystem, we're confident Integrated Oncology Network will further accelerate our oncology strategy and enable us to create value for providers and patients."  

    ION's business model and services are flexible and meet member practices where they are. Its support services include revenue cycle management, payor relations, physician recruitment, practice marketing, finance, accounting, human resources and information technology. Taken together with Navista offerings such as its technology platform and value-based care and ancillary services, ION complements and will expand Cardinal Health's holistic suite of clinical and practice management solutions designed to support independent community oncology practices.

    "Integrated Oncology Network and Cardinal Health share a mission of helping community oncology practices deliver world-class patient care and a world-class patient experience to patients and families close to home," said Barry Tanner, CEO, Integrated Oncology Network. "This partnership will give community practices the tools and technology they need to enhance and grow that mission and make a positive impact on patient outcomes."

    "By joining forces, Integrated Oncology Network and Cardinal Health are making an exciting commitment to community oncology and, most importantly, to the patients we serve across the country," said Jedidiah Monson, MD, founding partner and president of ION member practice California Cancer Associates for Research & Excellence (cCARE). "By joining Navista, cCARE can access the advanced services and technology we need to remain focused on providing high-quality, lower-cost patient-centered cancer care while staying independent—for the good of our patients, our practices and our communities."

    Cardinal Health's Pharmaceutical and Specialty Solutions segment operates one of the largest pharmaceutical supply chains in the U.S. with strategically located distribution centers that enable fast and efficient delivery anywhere in the country. Through its Specialty business, Cardinal Health provides reliable distribution and advanced technology solutions to community-based practices across the nation.

    This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. The transaction is expected to be accretive to non-GAAP earnings per share after 12 months following close.

    About Cardinal Health  

    Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com. 

    About Integrated Oncology Network  

    Integrated Oncology Network partners directly with physicians, hospitals and other healthcare providers to offer the latest services and technologies to their patients. Founded in 2008, ION has grown to more than 50 centers across the country, providing a complete and integrated continuum of care including diagnostic testing, radiation oncology, medical oncology, urology and other ancillary services. For more information, visit www.ionetwork.com.

    Contacts   

    Media: Andrea Bunce, [email protected] and (614) 553-3853

    Investors: Matt Sims, [email protected] and (614) 553-3661 

    Cautions Concerning Forward-Looking Statements  

    This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks associated with our planned acquisition of Integrated Oncology Network, including the risk that we may not receive required regulatory approval or otherwise fail to complete the acquisition and the risk that we may fail to realize the anticipated strategic and financial benefits. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of September 20, 2024. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this news release can or will be achieved or completed. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-to-acquire-integrated-oncology-network-a-physician-led-independent-community-oncology-network-302254191.html

    SOURCE Cardinal Health

    Get the next $CAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Buy
    Citigroup
    12/9/2025$243.00Overweight
    Barclays
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30

    DUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.About Card

    3/24/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair

    DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B. Kenny as Chair of the Board following Mr. Kenny's retirement, effective immediately. Mr. Kenny has served on the Board since 2007 and as Chairman since 2018. During his tenure on the Board, Mr. Kenny supported the Company through periods of significant transformation, including strategic portfolio evolution and operational improvement initiatives."On behalf of the Board and our management team, we are d

    3/23/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health report highlights cost savings and provider confidence in biosimilars

    New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.DUBLIN, Ohio, Feb. 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments. "Since 2015, biosimilars have generated more than $56 billion i

    2/24/26 7:00:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    Cardinal Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    3/23/26 6:48:23 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Leadership Update

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    3/5/26 7:07:59 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 8:47:09 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Greene Michelle D. sold $627,387 worth of shares (2,746 units at $228.47), decreasing direct ownership by 18% to 12,230 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    3/3/26 4:11:18 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Financial Officer Alt Aaron E covered exercise/tax liability with 1,914 shares and sold $524,964 worth of shares (2,328 units at $225.50), decreasing direct ownership by 14% to 26,408 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/18/26 4:25:35 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Director Hall Patricia Hemingway sold $918,880 worth of shares (4,000 units at $229.72), decreasing direct ownership by 12% to 28,264 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/10/26 4:13:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Citigroup

    Citigroup upgraded Cardinal Health from Neutral to Buy

    1/9/26 8:24:26 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cardinal Health with a new price target

    Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00

    12/9/25 8:43:24 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair

    DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B. Kenny as Chair of the Board following Mr. Kenny's retirement, effective immediately. Mr. Kenny has served on the Board since 2007 and as Chairman since 2018. During his tenure on the Board, Mr. Kenny supported the Company through periods of significant transformation, including strategic portfolio evolution and operational improvement initiatives."On behalf of the Board and our management team, we are d

    3/23/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care